Mobile Health and COVID-19: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Mobile Health and COVID-19 (NCT05074693), a randomized na study. The primary outcome is Everyday Impairment.

2. Clinical Question

3. Trial Design

The registry describes a randomized, parallel-group trial of the EASE app and the INSIGHT control app. Random allocation means assignment to an intervention group is determined by a random process; the specific method used to generate or implement the allocation is not reported in the registry record. In a parallel-group design, participants are assigned to a group and the groups are compared over the study period. The record lists no masking, so it does not describe participants or study personnel as blinded to assignment.

The recorded enrollment is 822. The sponsor is the University of Houston, the study status is completed, and the recorded start and primary completion dates are 2021-12-20 and 2024-01-26. The phase is listed as NA. These record fields describe the study's registration and status; they do not provide information about adherence, follow-up completion, or the number of participants included in an outcome analysis.

The intervention descriptions distinguish EASE's educational videos, tailored messages, and interoceptive exercises from INSIGHT's mindfulness and meditation videos. The broader study summary says the research was designed to assess EASE in relation to public health risks and mental health during the COVID-19 pandemic and to identify mechanisms that might account for its effects. The registry record does not report the procedures used to assess those mechanisms or the findings from those assessments.

The registered primary outcome is everyday impairment, assessed from baseline to 6-month follow-up. Eight secondary outcome topics are listed, including perceived discrimination, social support, anxiety sensitivity, fear of COVID-19, and acculturation. The record lists 11 outcome measures, but reports 0 analyses. Thus, the design and planned measurement topics can be described, while conclusions about comparative effects cannot be drawn from the registry results reported in this record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Everyday Impairment, measured over From Baseline to 6-Months.

The primary endpoint is everyday impairment related to reported anxiety and depression. The description identifies major life sectors—work performance, household maintenance, social interactions, and relationships—as areas in which impairment is assessed. The measure uses study-developed items and is intended to capture change from baseline to follow-up rather than a single status at one moment.

The registry describes a four-item scale, with each item rated from 1 (Strongly disagree) to 5 (Strongly agree), and reports a total-score range from 4 to 25. Higher scores are described as indicating greater everyday impairment. The record identifies the outcome as a mean of a continuous measure and specifies standard deviation as its dispersion measure.

In general, a continuous score can retain gradations in participants' reported experience, rather than reducing the outcome to a yes-or-no category. Repeated assessment can describe change over time, and a between-group comparison can address whether the average changes differ between assigned interventions. Those are general reasons such a measure may be used; they do not establish that the scale is reliable, valid, or sensitive to change in this study. The registry record does not report psychometric evidence, a threshold for an important change, or the primary endpoint results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Randomization and a parallel-group structure describe how a trial organizes its comparison, but they do not by themselves specify the statistical analysis. The registry identifies randomized allocation and two app groups. It does not report the allocation-generation procedure, concealment method, or a detailed statistical analysis plan. Those distinctions matter because the quality of implementation and the chosen analysis affect how a result should be interpreted.

What does a comparison of means represent?

The primary outcome is described as a continuous score, with the mean as the parameter of interest and the standard deviation as the dispersion measure. In general, a mean represents the average score in a group. A standard deviation describes how spread out individual scores are around that group average. The mean and standard deviation answer different questions: one locates the group average, while the other describes variability among observations.

A trial may compare group means at follow-up, compare changes from baseline, or use a model that accounts for baseline values and repeated measurements. These approaches are not interchangeable in every circumstance, and their assumptions differ. The registry record identifies a baseline-to-follow-up timeframe but does not report which specific model or contrast was used. It is therefore not possible to state whether the intended comparison was based on follow-up scores, change scores, or an adjusted repeated-measures analysis.

Why does the analysis model matter?

In general, a statistical model translates observed data into an estimate of a group contrast and its uncertainty. Model choice should reflect the outcome type, measurement schedule, randomization, and data structure. For a continuous endpoint, model assumptions may concern the form of the outcome distribution, the relationship between repeated observations, and the way covariates are handled. The registry record does not report the model, covariates, variance assumptions, or diagnostics used for the primary outcome.

In general, confidence intervals help communicate precision by showing a range of estimates compatible with the data and model. A narrow interval indicates greater precision than a wide interval, though precision is not the same as importance. Statistical significance is also not a measure of clinical or practical importance. A useful interpretation would consider the estimated contrast, its uncertainty, the scale's meaning, and an appropriate threshold for a meaningful difference. The record does not report the estimate, interval, significance test, or a threshold for meaningful change.

What does random allocation contribute?

In general, random assignment aims to make groups comparable at the start with respect to measured and unmeasured characteristics, on average across repeated assignments. It does not guarantee identical groups in a particular trial, and it does not prevent missing follow-up data, non-adherence, or measurement problems. The trial record states that allocation was randomized but does not provide baseline comparisons or information about adherence. No conclusions about these features can be drawn from the registration fields alone.

The record specifies no masking. In general, lack of masking can affect expectations, reported experiences, engagement, or assessment, particularly when outcomes are self-reported. This is a possible design consideration, not proof that bias occurred. The endpoint is based on reported impairment, but details of administration and procedures to limit measurement bias are not reported in the registry record.

How should the sample-size material be understood?

In general, a sample-size calculation is a planning exercise tied to assumptions about the effect to detect, variability, allocation, significance level, and desired power. A planning illustration based on an observed effect is not an observed-power result and does not show that a trial was adequately powered for its actual outcomes. The registry record does not report the original design justification, the target effect used by investigators, or a protocol-based sample-size rationale. No numerical planning estimates are stated in the registry record.

In general, over-dispersion means that variability is greater than a model assumes; if ignored, uncertainty may be understated and tests may be poorly calibrated. This issue is relevant when the data structure or outcome distribution makes a simple variance assumption unsuitable. The primary outcome is described as continuous, but the record does not report evidence of over-dispersion or the model used to assess variability. It would be inappropriate to claim that over-dispersion occurred or that it was addressed.

The registry lists 0 analyses and does not provide an outcome estimate or analysis specification for the primary comparison. As a result, the statistical methods actually used to estimate the intervention contrast, quantify uncertainty, handle repeated scores, and address model assumptions are not reported in the registry record. General explanations of statistical methods cannot fill those gaps or serve as a substitute for the sponsor's reported analysis.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists 11 outcome measures and identifies multiple secondary topics in addition to everyday impairment. When several outcomes, time points, or comparisons are tested, the chance of at least one apparently unusual result can increase. In general, multiplicity procedures may control that risk, or a prespecified hierarchy may identify which comparisons are confirmatory. The registry record does not report a multiplicity strategy, a hierarchy of outcomes, or how repeated time points were handled.

The record indicates that the primary outcome has several categories or time points and was not reduced to one comparison. It also reports 0 analyses. No primary or secondary estimates, tests, or intervals are reported. Without these details, it is not possible to determine which comparisons were conducted, whether results were selected from a larger set, or whether an adjustment was used. The listing of outcomes alone should not be interpreted as evidence that every listed measure was analyzed or showed a particular pattern.

Missing data are another important consideration for a baseline-to-follow-up endpoint. In general, missing outcome measurements can reduce precision and can bias a group comparison if missingness relates to outcome values or differs between groups. Analyses may use different assumptions or methods to address incomplete observations, and sensitivity analyses can assess how conclusions depend on those choices. The registry record does not report the amount or pattern of missing data, the number included in the primary analysis, the missing-data method, or sensitivity analyses.

The analysis population is also not reported in the registry record. In general, an intention-to-treat analysis keeps participants in the groups to which they were randomized, while other analysis populations may impose additional requirements. The record does not state which population was used or how deviations from assigned intervention were treated. Accordingly, neither the handling of missing outcomes nor the population underlying a primary estimate can be assessed from the posted results.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The safety record lists the EASE group with 413 participants at risk for serious adverse events and 413 at risk for other adverse events. It records 0 serious adverse events, 0 other adverse events, and 0 deaths for that group. The INSIGHT control group has 409 participants at risk for each adverse-event category, with 0 serious adverse events, 0 other adverse events, and 0 deaths recorded.

These are the registry's event counts and at-risk group sizes. They indicate that the posted safety entries contain no recorded events in either group; they do not establish that no symptoms or other health experiences occurred. The registry record does not report event definitions, collection methods, observation time by participant, event adjudication, or the handling of events not meeting the recorded categories.

In general, safety counts should be read in relation to the population monitored and the way events were sought and classified. Zero recorded events do not prove that an intervention has no risk, particularly when details about surveillance and exposure time are absent. No rates or comparative safety estimates are reported in the registry record, and none can be inferred from the counts alone.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a randomized, parallel-group comparison was registered for the EASE app and the INSIGHT control app, with everyday impairment identified as the primary outcome. It also describes the outcome's content, scoring direction, and baseline-to-6-month timeframe. These registry entries explain what the study set out to compare; they do not reveal what the comparison found.

The posted record does not include primary outcome group summaries, a between-group estimate, a confidence interval, or an analysis result. It therefore does not show whether everyday impairment changed, whether changes differed between groups, or how precisely any difference was estimated. The completed status should not be treated as an outcome finding, and the registration's description of intervention aims should not be treated as evidence that those aims were achieved.

The record also lists several secondary outcome topics and safety counts. Listing a topic does not establish a result for that topic. The absence of recorded adverse events in the safety fields is limited to those entries and does not answer the primary effectiveness question. Likewise, a randomized design can support causal interpretation when implemented and analyzed appropriately, but it cannot replace the missing outcome results and methods needed to evaluate the actual comparison.

In general, a measured difference is not automatically a clinically meaningful difference. Its importance depends on the magnitude, uncertainty, measurement properties, and a defensible interpretation of the scale. The registry record does not provide the comparative estimate or a threshold for meaningful change. The available information therefore supports a description of the trial and its registered questions, but not a conclusion about the size, direction, precision, or practical importance of an intervention effect.

13. Why This Trial Matters Statistically

This trial is statistically notable for combining a randomized app comparison with a self-reported, study-developed continuous outcome focused on everyday functioning. The endpoint links anxiety- and depression-related impairment to work performance, household maintenance, social interactions, and relationships. That framing makes clear that the study sought to measure reported effects in daily life, rather than only a general attitude toward an app.

The study summary also foregrounds health disparities among Black, Hispanic and Latino, and American Indian individuals during the COVID-19 pandemic. This makes the population and context important to interpretation. However, the registry record does not provide eligibility details, subgroup definitions, participant characteristics, or subgroup analyses. The stated focus should not be mistaken for evidence that the enrolled sample represented those communities or that effects differed across groups.

Statistically, the contrast between EASE and an active digital comparator is relevant because the comparator is described as offering mindfulness and meditation educational videos. The study therefore registered a comparison between two app-based approaches, not a comparison with no app. That distinction would matter when interpreting any observed contrast, but comparative estimates are not reported in the registry record.

The record's lack of outcome analyses also illustrates a basic interpretive boundary: a clear question and a completed trial do not themselves provide evidence about an effect. Without estimates, uncertainty, analysis-population details, and missing-data methods, readers cannot assess the strength or precision of the primary comparison. The registry is informative about the question and measurements, while leaving the central statistical answer unreported.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting this trial record is the absence of reported outcome analyses. Although everyday impairment is identified as the primary outcome and the study status is completed, the registry lists 0 analyses and supplies no comparative results. No conclusion about the direction, size, or precision of the primary contrast is supported.

The endpoint is described as a study-developed measure. The registry record gives the item format and scoring interpretation but does not report evidence about reliability, validity, responsiveness, or a threshold for meaningful change. The listed score range is 4 to 25. Further documentation would be needed to assess how the measure was developed and how scores should be interpreted beyond the stated direction.

Important design and analysis details are not reported in the registry record. These include eligibility criteria, participant characteristics, allocation procedures, adherence, the primary analysis model, baseline adjustment, analysis populations, outcome missingness, and sensitivity analyses. The record also does not describe a multiplicity approach for the several outcome measures and time points. These omissions prevent a detailed assessment of bias, precision, and robustness.

The registry describes no masking and a self-reported impairment outcome. In general, awareness of assignment can influence reporting or engagement, but the record does not establish that this happened. The safety entries also lack details about event definitions and monitoring. Finally, the study summary's focus on particular communities is not accompanied by subgroup results or population detail in the registry record, limiting assessment of how broadly the findings might apply even if comparative results were available.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Mobile Health and COVID-19 — NCT05074693.
• Registry record last updated 2026-06-12; status last verified 2026-05.
• Results first posted 2025-09-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The record describes a completed, randomized, parallel-group study sponsored by the University of Houston, with recorded enrollment of 822 and no masking. It compares the EASE app with the INSIGHT control app. EASE is described as using educational videos, tailored messages, and interoceptive exercises; INSIGHT is described as offering mindfulness and meditation videos.

The primary outcome is everyday impairment related to anxiety and depression, measured from baseline to 6-month follow-up using a study-developed scale. The registry lists 11 outcome measures and 0 analyses, and the primary outcome was not reduced to one comparison. No comparative outcome estimates are reported in the registry record. The safety fields record 0 serious adverse events, 0 other adverse events, and 0 deaths in each group.

The record documents the trial question and measurement plan, but does not report the statistical analysis or results needed to judge the primary comparison.